Unspecified

This product is a second-generation cephalosporin antibiotic. The antibacterial activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against beta-lactamase produced by Staphylococci and Gram-negative bacilli. Methicillin-resistant Staphylococci, Enterococci and Listeria are resistant, and other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity against Staphylococcus aureus is worse than that of cefazolin, and 1-2 mg/L can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, and Escherichia coli, Proteus mirabilis, etc. may be sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter have poor sensitivity to this product, most Serratia are resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

Belongs to other classes of antianginal cardiovascular drugs

It has strong anti-inflammatory, liver cell membrane protection and liver function improvement effects. It can reduce the increase of serum alanine aminotransferase and aspartate aminotransferase caused by carbon tetrachloride, thioacetamide and D-galactosamine, significantly reduce the morphological damage of D-galactosamine to the liver and improve the chronic damage of immune factors to the liver morphology.

It relaxes vascular smooth muscle, activates guanylate cyclase by releasing nitric oxide (NO), increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby dilating peripheral arteries and veins, reducing the amount of blood returning to the heart, lowering left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload), reducing peripheral vascular resistance, systolic arterial pressure and mean arterial pressure (afterload), dilating coronary arteries to increase coronary perfusion, and ultimately reducing myocardial oxygen consumption and increasing oxygen supply.